Optimized synthesis and pharmacological evaluation of HCN channel inhibitor EC18.
Arch Pharm (Weinheim)
; 356(6): e2200665, 2023 Jun.
Article
em En
| MEDLINE
| ID: mdl-36949271
ABSTRACT
HCN4 channels are considered to be a promising target for cardiac pathologies, epilepsy, and multiple sclerosis. However, there are no subtype-selective HCN channel blockers available, and only a few compounds are reported to display subtype preferences, one of which is EC18 (cis-1). Herein, we report the optimized synthetic route for the preparation of EC18 and its evaluation in three different pharmacological models, allowing us to assess its activity on cardiac function, thalamocortical neurons, and immune cells.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Canais de Potássio
/
Canais de Cátion Regulados por Nucleotídeos Cíclicos
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article